Susana Ourô

Dr. Susana Ourô

Hospital Beatriz Ângelo
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2014 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
ISIrshad Shaikh
Irshad Shaikh
AAAlan Askari
Alan Askari
Susana OurôSusana Ourô
Susana Ourô
JWJanindra Warusavitarne
Janindra Warusavitarne
TAThanos Athanasiou
Thanos Athanasiou
OFOmar Faiz
Omar Faiz

14 April 2021 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
Susana OurôSusana Ourô
Susana Ourô
MFMarisa P. Ferreira
Marisa P. Ferreira
DADiogo Albergaria
Diogo Albergaria
RMRui Maio
Rui Maio

1 January 2020 in Nutrition
Verified
Journal Article
Open access
MCMaria Pia Costa-Santos
Maria Pia Costa-Santos
CPCarolina Palmela
Carolina Palmela
JTJoana Torres
Joana Torres
AFAndreia Ferreira
Andreia Ferreira
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
MCMarília Cravo
Marília Cravo
The use of exclusive enteral nutrition (EEN) in patients with Crohn's disease (CD) before surgical resection can reduce disease activity and improve nutritional status. The mechanism of EEN action is unclear, but it might involve modulation of the intestinal microbiota. The aim of this study was to evaluate the effects (namely changes in gut microbiota) of preoperative EEN in adults with complicated CD referred to surgery. This was a prospective study of adult patients with CD referred to surgery. Patients with body mass index 10 %, serum albumin <3 g/dL, or a combination of some or all three, received EEN for ≥2 wk. The effects of EEN on clinical (Harvey-Bradshaw Index [HBI]) and laboratory markers (C-reactive protein [CRP], serum albumin, and fecal calprotectin) and fecal microbiota were analyzed after EEN (before surgery) and 6 mo later. We used 16 S rRNA gene sequencing to determine changes in the fecal microbiota. Fifteen patients were included, of whom 60% were men with a mean age of 45.4 ± 19.1 y. Of those, 10 received EEN. The median duration of preoperative EEN was 41.5 d (15-70 d). During EEN, there was a significant reduction in mean HBI (8.7 ± 1.9 versus 4.1 ± 2.4; P = 0.001) and CRP (11.7 ± 10.3 versus 0.8 ± 0.8 mg/dL; P = 0.008) and an increase in serum albumin (3.1 ± 0.6 versus 4 ± 0.6 g/dL; P = 0.022). Two patients did not require surgery after EEN. The overall microbial composition changed after EEN (Permutational analysis of variance test, P = 0.046) and there was a significant reduction in α diversity (8 ± 2.3 versus 5.2 ± 1.5; P = 0.023). EEN significantly changed the relative abundance of 11 taxonomic operational units (OTUs). At the family level, we found this was mainly due to the decrease in the Enterobacteriaceae family (7 OTUs). Six months after surgery, α diversity was not different from that before or after EEN; at this time point 6 OTUs were significantly different, mainly due to the decrease of Clostridiales order (3 OTUs). The incidence of postoperative complications and hospital length of stay were similar in EEN and immediate surgery groups, as well as clinical and endoscopic recurrence rates 6 mo after surgery. Preoperative EEN improved disease activity and nutritional status in patients with CD referred to surgery. Despite being malnourished, patients given EEN did not have increased postoperative complications compared with well-nourished patients. During EEN, overall microbiota composition changed and α diversity decreased. EEN did not influence postoperative recurrence and gut microbiota 6 mo after surgery.

2 December 2016 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
Susana OurôSusana Ourô
Susana Ourô
BTB. Thava
B. Thava
ISI. Shaikh
I. Shaikh
SCSusan Clark
Susan Clark

20 January 2022 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
Susana OurôSusana Ourô
Susana Ourô
MFM. Ferreira
M. Ferreira
PRP. Roquete
P. Roquete
RMR. Maio
R. Maio

27 October 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Susana OurôSusana Ourô
Susana Ourô
CMCláudia Mourato
Cláudia Mourato
SVSónia Velho
Sónia Velho
ACAndré Cardador
André Cardador
MFMarisa P. Ferreira
Marisa P. Ferreira
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Background: Patients with locally advanced rectal adenocarcinoma (LARC) are treated with neoadjuvant chemoradiotherapy (CRT). However, biomarkers for patient selection are lacking, and the association between miRNA expression and treatment response and oncological outcomes is unclear. Objectives: To investigate miRNAs as predictors of response to neoadjuvant CRT and its association with oncological outcomes. Methods: This retrospective study analyzed miRNA expression (miR-16, miR-21, miR-135b, miR-145, and miR-335) in pre- and post-chemoradiation rectal adenocarcinoma tissue and non-neoplastic mucosa in 91 patients treated with neoadjuvant CRT (50.4 Gy) and proctectomy. Two groups were defined: a pathological complete responders group (tumor regression grade—TRG 0) and a pathological incomplete responders group (TRG 1, 2, and 3). Results: miR-21 and miR-135b were upregulated in tumor tissue of incomplete responders comparing with non-neoplastic tissue (p = 0.008 and p < 0.0001, respectively). Multivariate analysis showed significant association between miR-21 in pre-CRT tumor tissue and response, with a 3.67 odds ratio (OR) of incomplete response in patients with higher miR-21 levels (p = 0.04). Although with no significance, patients treated with 5-fluorouracil (5-FU) presented reduced odds of incomplete response compared with those treated with capecitabine (OR = 0.19; 95% confidence interval (CI) 0.03–1.12, p = 0.05). Moreover, significant differences were seen in overall survival (OS) in relation to clinical TNM stage (p = 0.0004), cT (p = 0.0001), presence of distant disease (p = 0.002), mesorectal tumor deposits (p = 0.003), and tumor regression grade (p = 0.04). Conclusion: miR-21 may predict response to CRT in rectal cancer (RC).